MiMedx Group (MDXG) investor relations material

Business profile and Q3 performance

• Surgical represented two-thirds of Q3 revenue; sales were $62M, including $40M surgical, with surgical dollars up 9% and volume up mid-teens YoY.

• Q3 gross margin was 80%; cost discipline drove a sequential swing to positive adjusted EBITDA and free cash flow, with $121M cash and no debt at quarter-end.

• Wound care faced disruption from Medicare reimbursement reforms effective Jan. 1, 2026; 2027 PFS and OPPS rates keep the 2026 measures in place.

• A favorable court ruling involved AXIOFILL, and a structured $25M settlement resolved IP infringement allegations with a wound care competitor.

Pending Sanara acquisition

• Sanara is 100% operating-room focused and has over $100M in revenue; its agent network and product lineup are expected to expand commercial reach and surgical offerings.

• The deal would add over $4B in addressable markets, including no-rinse irrigation and bone fixation; combined surgical revenue would be about three-quarters of total revenue.

• In the first year after combination, management expects roughly $400M in revenue and adjusted EBITDA margins above 20%; the transaction is expected to immediately accrete to revenue growth and profitability.

• Required approvals were secured except for FTC clearance; the parties were working through the agency’s Second Request, seeking completion as quickly as possible.

Surgical growth and evidence

• The U.S. has over 91M surgical procedures annually; Q3 surgical sales were $40M, with double-digit volume growth supported by expanding clinical evidence.

• HELIOGEN and G4Derm Plus added to surgical growth; two 510(k) submissions were under FDA review, with launches targeted for the near term.

• Published data for AMNIOFIX grafts showed roughly half the anastomotic leak rate and an almost equivalent reduction in 30-day readmissions.